Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that CEO Robb Knie will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 12:10 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that CEO Robb Knie will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 12:10 p.m. ET. Following this, he will join a panel discussion titled 'Coming Together to Address Unmet Medical Needs' at 12:50 p.m. ET.
Interested attendees can register for the webcast by visiting Benzinga's event page. Hoth Therapeutics focuses on developing therapies for dermatological disorders and has recently advanced vaccine projects for COVID-19.
Details
News Market Reaction – HOTH
The recorded move for HOTH in the trading session of this news was -1.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Benzinga Biotech Small Cap Conference on Wednesday, March 24th at 12:10 p.m. ET. Following the presentation, Mr. Knie will also participate in a panel discussion on the same day at 12:50 p.m. ET, entitled 'Coming Together to Address Unmet Medical Needs'.
To attend the conference and listen to the presentation and panel discussion via webcast, please register by visiting https://www.benzinga.com/events/small-cap/biotech/.
For more information regarding the conference or to schedule a one-on-one meeting with management, please email investorrelations@hoththerapeutics.com or your Benzinga representative directly.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-present-at-the-benzinga-biotech-small-cap-conference-on-march-24-2021-301252395.html
SOURCE Hoth Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.